Mersana Therapeutics Inc MRSN.OQ MRSN.O is expected to show a fall in quarterly revenue when it reports results on February 26 (estimated) for the period ending December 31 2024
The Cambridge Massachusetts-based company is expected to report a 28.3% decrease in revenue to $7.673 million from $10.7 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for Mersana Therapeutics Inc is for a loss of 16 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Mersana Therapeutics Inc is $5.00, above its last closing price of $0.53.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.18 | -0.18 | -0.09 | Beat | 48.7 |
Jun. 30 2024 | -0.17 | -0.17 | -0.20 | Missed | -16.7 |
Mar. 31 2024 | -0.18 | -0.18 | -0.16 | Beat | 11.6 |
Dec. 31 2023 | -0.12 | -0.16 | -0.16 | Met | 2.6 |
Sep. 30 2023 | -0.35 | -0.36 | -0.27 | Beat | 25.4 |
Jun. 30 2023 | -0.37 | -0.44 | -0.47 | Missed | -6.5 |
Mar. 31 2023 | -0.40 | -0.44 | -0.52 | Missed | -19.3 |
Dec. 31 2022 | -0.47 | -0.50 | -0.44 | Beat | 12.8 |
This summary was machine generated February 24 at 13:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。